Advancing a diversified portfolio of first-in-class gene therapies  

Opus’ programs focus on treatments for inherited retinal diseases (IRDs) to address mutations in genes that cause loss of vision, including Leber congenital amaurosis (LCA), Best vitelliform macular dystrophy (BVMD), and retinitis pigmentosa (RP). We also have a novel, small molecule program under collaboration with a commercial partner.